Literature DB >> 17483311

CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.

Dagmar Beier1, Peter Hau, Martin Proescholdt, Annette Lohmeier, Jörg Wischhusen, Peter J Oefner, Ludwig Aigner, Alexander Brawanski, Ulrich Bogdahn, Christoph P Beier.   

Abstract

Although glioblastomas show the same histologic phenotype, biological hallmarks such as growth and differentiation properties vary considerably between individual cases. To investigate whether different subtypes of glioblastomas might originate from different cells of origin, we cultured tumor cells from 22 glioblastomas under medium conditions favoring the growth of neural and cancer stem cells (CSC). Secondary glioblastoma (n = 7)-derived cells did not show any growth in the medium used, suggesting the absence of neural stem cell-like tumor cells. In contrast, 11/15 primary glioblastomas contained a significant CD133(+) subpopulation that displayed neurosphere-like, nonadherent growth and asymmetrical cell divisions yielding cells expressing markers characteristic for all three neural lineages. Four of 15 cell lines derived from primary glioblastomas grew adherently in vitro and were driven by CD133(-) tumor cells that fulfilled stem cell criteria. Both subtypes were similarly tumorigenic in nude mice in vivo. Clinically, CD133(-) glioblastomas were characterized by a lower proliferation index, whereas glial fibrillary acidic protein staining was similar. GeneArray analysis revealed 117 genes to be differentially expressed by these two subtypes. Together, our data provide first evidence that CD133(+) CSC maintain only a subset of primary glioblastomas. The remainder stems from previously unknown CD133(-) tumor cells with apparent stem cell-like properties but distinct molecular profiles and growth characteristics in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483311     DOI: 10.1158/0008-5472.CAN-06-4180

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  476 in total

Review 1.  Potential therapeutic implications of cancer stem cells in glioblastoma.

Authors:  Lin Cheng; Shideng Bao; Jeremy N Rich
Journal:  Biochem Pharmacol       Date:  2010-05-10       Impact factor: 5.858

2.  Integrin alpha 6 regulates glioblastoma stem cells.

Authors:  Justin D Lathia; Joseph Gallagher; John M Heddleston; Jialiang Wang; Christine E Eyler; Jennifer Macswords; Qiulian Wu; Amit Vasanji; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cell Stem Cell       Date:  2010-05-07       Impact factor: 24.633

3.  CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion.

Authors:  Noriyuki Kijima; Naoki Hosen; Naoki Kagawa; Naoya Hashimoto; Akiko Nakano; Yasunori Fujimoto; Manabu Kinoshita; Haruo Sugiyama; Toshiki Yoshimine
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

4.  The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion.

Authors:  Mei Yee Koh; Robert Lemos; Xiuping Liu; Garth Powis
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

5.  Evidence for label-retaining tumour-initiating cells in human glioblastoma.

Authors:  Loic P Deleyrolle; Angus Harding; Kathleen Cato; Florian A Siebzehnrubl; Maryam Rahman; Hassan Azari; Sarah Olson; Brian Gabrielli; Geoffrey Osborne; Angelo Vescovi; Brent A Reynolds
Journal:  Brain       Date:  2011-04-22       Impact factor: 13.501

6.  Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma.

Authors:  Rong Shao; Ralph Francescone; Nipaporn Ngernyuang; Brooke Bentley; Sherry L Taylor; Luis Moral; Wei Yan
Journal:  Carcinogenesis       Date:  2013-11-26       Impact factor: 4.944

7.  Transcriptional profiling of dividing tumor cells detects intratumor heterogeneity linked to cell proliferation in a brain tumor model.

Authors:  Berwini B Endaya; Paula Y P Lam; Adrian C B Meedeniya; Jiri Neuzil
Journal:  Mol Oncol       Date:  2015-09-10       Impact factor: 6.603

8.  SIRT1 is required for oncogenic transformation of neural stem cells and for the survival of "cancer cells with neural stemness" in a p53-dependent manner.

Authors:  Ji-Seon Lee; Jeong-Rak Park; Ok-Seon Kwon; Tae-Hee Lee; Ichiro Nakano; Hiroyuki Miyoshi; Kwang-Hoon Chun; Myung-Jin Park; Hong Jun Lee; Seung U Kim; Hyuk-Jin Cha
Journal:  Neuro Oncol       Date:  2014-08-05       Impact factor: 12.300

Review 9.  Glioblastoma stem cells: Molecular characteristics and therapeutic implications.

Authors:  Nermin Sumru Bayin; Aram Sandaldjian Modrek; Dimitris George Placantonakis
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

10.  Cancer stem cells are enriched in the side population cells in a mouse model of glioma.

Authors:  Molly A Harris; Hyuna Yang; Benjamin E Low; Joydeep Mukherjee; Joydeep Mukherje; Abhijit Guha; Roderick T Bronson; Leonard D Shultz; Mark A Israel; Kyuson Yun
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.